zoster vaccine recombinant-Abramson Cancer Center at Penn Medicine-influenza-COVID-19-herpes zoster

This entry refers to a specific vaccination regimen evaluated in clinical research led by the Abramson Cancer Center at Penn Medicine. The regimen involves the administration of three distinct vaccines: the recombinant zoster vaccine (Shingrix), an inactivated influenza vaccine, and a SARS-CoV-2 (COVID-19) vaccine. The recombinant zoster vaccine is a non-live, adjuvanted subunit vaccine containing the varicella-zoster virus glycoprotein E antigen, designed to prevent herpes zoster (shingles) by inducing a robust T-cell mediated immune response. The influenza and SARS-CoV-2 vaccines target their respective viral surface proteins (hemagglutinin and spike protein) to provide seasonal and pandemic protection. The primary focus of the associated study (NCT04778592) is to assess the immunogenicity and safety of these standard-of-care vaccinations in patients diagnosed with cancer, who may have compromised immune responses due to malignancy or oncologic treatments.

Brand names

Shingrix

Other names

influenza vaccine + SARS-CoV-2 vaccine + zoster vaccine recombinantShingrixSARS-CoV-2 vaccineSARS-CoV2 vaccineSARS-CoV 2 vaccineInfluenza vaccineVaccine Responses in Cancer study vaccines